Janney Montgomery Scott LLC Has $3.31 Million Position in Sanofi SA (SNY)
Janney Montgomery Scott LLC trimmed its position in Sanofi SA (NYSE:SNY) by 14.5% in the 3rd quarter, HoldingsChannel reports. The fund owned 73,994 shares of the company’s stock after selling 12,518 shares during the quarter. Janney Montgomery Scott LLC’s holdings in Sanofi were worth $3,305,000 as of its most recent filing with the Securities and Exchange Commission.
A number of other institutional investors have also recently added to or reduced their stakes in SNY. Squar Milner Financial Services LLC purchased a new stake in Sanofi in the 2nd quarter worth approximately $169,000. Stratos Wealth Partners LTD. purchased a new stake in Sanofi during the 3rd quarter valued at approximately $174,000. New England Research & Management Inc. purchased a new stake in Sanofi during the 3rd quarter valued at approximately $205,000. Nisa Investment Advisors LLC purchased a new stake in Sanofi during the 3rd quarter valued at approximately $205,000. Finally, Natixis purchased a new stake in Sanofi during the 2nd quarter valued at approximately $213,000. 7.47% of the stock is owned by institutional investors.
NYSE SNY opened at $45.10 on Friday. The company has a quick ratio of 0.85, a current ratio of 1.22 and a debt-to-equity ratio of 0.40. The company has a market cap of $112.61 billion, a PE ratio of 14.41, a PEG ratio of 2.54 and a beta of 0.70. Sanofi SA has a one year low of $37.43 and a one year high of $46.25.
SNY has been the subject of a number of research analyst reports. Citigroup raised shares of Sanofi from a “neutral” rating to a “buy” rating in a report on Friday, August 10th. Wolfe Research initiated coverage on shares of Sanofi in a report on Tuesday, October 23rd. They set a “market perform” rating for the company. Zacks Investment Research lowered shares of Sanofi from a “hold” rating to a “sell” rating in a report on Tuesday, October 16th. JPMorgan Chase & Co. reaffirmed a “neutral” rating on shares of Sanofi in a report on Wednesday, October 31st. Finally, Barclays raised shares of Sanofi from an “underweight” rating to an “equal weight” rating in a report on Thursday, November 1st. Two analysts have rated the stock with a sell rating, nine have assigned a hold rating and six have issued a buy rating to the company’s stock. The stock has an average rating of “Hold” and a consensus target price of $49.50.
In other news, major shareholder Sanofi sold 104,552 shares of the stock in a transaction that occurred on Thursday, September 6th. The stock was sold at an average price of $406.68, for a total transaction of $42,519,207.36. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. 1.00% of the stock is currently owned by corporate insiders.
Sanofi provides therapeutic solutions. It offers Cerezyme and Cerdelga for Gaucher disease, Myozyme and Lumizyme for Pompe disease, Fabrazyme for Fabry disease, and Aldurazyme for mucopolysaccharidosis Type 1; Aubagio, an oral immunomodulatory; and Lemtrada, a monoclonal antibody to treat multiple sclerosis.
Featured Article: Trading Strategy Methods for Individual Investors
Want to see what other hedge funds are holding SNY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Sanofi SA (NYSE:SNY).
Receive News & Ratings for Sanofi Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sanofi and related companies with MarketBeat.com's FREE daily email newsletter.